• Plus Products releases PLUS CBDRelief brand into the California adult-use market
• New product line currently includes two products: PLUS CBDRelief 9:1 Tropical Mango and PLUS CBDRelief 18:1
• PLUS CBDRelief products specifically formulated to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind

With its gummy products consistently ranking tops in California, the world’s largest cannabis market, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is focusing its current efforts on maintaining its best-selling spot as well as expanding market share in a category that has historically remained underserved. PLUS plans to accomplish both with the launch of its newest line of products – two high-CBD, low-THC gummies designed to fill a hole in the wellness and relief-market cannabis category.

This month Plus Products released its PLUS CBDRelief brand into the California adult-use market (http://ibn.fm/R6Enj). The product line currently includes two products: PLUS CBDRelief 9:1 Tropical Mango with 9 mg of CBD and 1 mg of THC per serving and PLUS CBDRelief 18:1 Tart Cherry with 18 mg of CBD and 1 mg of THC per serving. The PLUS CBDRelief cannabis-infused gummies are expected to be available statewide in coming weeks.

“We have seen compelling success with our core brand and are excited to take the next step towards becoming a true portfolio of brands with the launch of PLUS CBDRelief,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Last year we partnered with market structure research firm HJR Associates and found that when consumers used cannabis, over one-third of the time it was to address pain, stress or anxiety. This represents a massive market that appears, thus far, to have been underserved. We believe there are almost no edibles products in California designed to meet the needs of these consumers, and we’re excited to introduce products formulated specifically for that purpose.”

PLUS CBDRelief products are specifically formulated to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind. The proprietary products contain an exclusive mix of high-quality CBD and THC to deliver the highest cannabinoid content per package among gummies in the California marketplace; the products are also deliberately designed in dosages that enable consumers to precision dose, or control the dosages they receive based on individual response and desires.

The new PLUS CBDRelief brand is a strong addition to Plus Products core brand, which was the largest cannabis-infused gummies brand in California in 2019 and ranked as the best-selling cannabis product in the state across all categories over the same period.

“Research suggests that people are looking to cannabis as a holistic tool for relief,” PLUS Chief Scientific Officer Ari Mackler stated in a news release. “It’s exciting to leverage rigorous science to formulate great products that enable people to help themselves. Research on cannabis is progressing quickly, and we are driving our portfolio of products with innovative science and technologies that will support our customers’ health and wellness goals.”

Plus Products is well positioned for greater growth in California. The company has also taken its top-selling product into Nevada. Of note for investors is that PLUS has a strong management team and a clean capital structure with considerable insider ownership. The company continues to build the world’s largest cannabis brand by applying its successful formula to new products and consumers.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Kitz brings with him more than two decades of experience, global perspective of innovation and manufacturing gained from Siemens career
• “Exro has the potential to add significant value to industrial sectors worldwide,” said Kitz
• New board member’s insight, ingenuity, experience will help “accelerate the commercialization of Exro technology into the global marketplace,” XRO COO observed

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), whose technology unlocks the unrealized power within the world’s electric motors, has announced that Werner Kitz, an industry leader in electric motors and drives, has joined the Exro Business Advisory Board.

A senior executive and engineer at Siemens who retired in 2019, Kitz brings with him more than 25 years of experience and a global perspective of innovation and manufacturing in the power-conversion sector (http://ibn.fm/mk213). He will be advising Exro as the company continues its aggressive commercialization program to improve the performance of electric motors used in the automotive, energy, agricultural, marine and last-mile transportation space, among others.

“I am happy to join the Business Advisory Board to assist Josh and the Exro team in bringing Exro’s technology to market,” Kitz stated in a news release. “Exro has the potential to add significant value to industrial sectors worldwide, ensuring we get more from the energy we use to power electric motors and powertrains.”

A 1981 graduate of Rheinisch-Westfälische Technische Hochschule Aachen (RWTH-Aachen), Kitz spent his time at the university focused on motors, drives and power distribution. He obtained employment at Siemens as an electrical engineer at the company’s motor factory in Nuremberg, Germany, where he made an immediate impression with his insight and expertise. He was promoted within a year to Siemens’ headquarters to concentrate on engineering and automation in the metals aspect of the industry.

By 1998, Kitz was serving as director of engineering for Siemens’ large drives division in global markets, where he shouldered responsibilities for innovation in variable speed drives for metals, O&G, and test stands; he also took on new market development for high-power and high-torque applications. In 2014, he was named vice president of mill drives in the company’s minerals industry division.

“Werner has played a major role at Siemens – and the world’s electrical motor and drive sector – for more than a quarter of a century,” Exro COO Josh Sobil stated in a news release. “Werner’s insight, ingenuity and experience will help us accelerate the commercialization of Exro technology into the global marketplace.”

Kitz joins a group of individuals with impressive experience in the industry including Sue Ozdemir, who was appointed Exro’s CEO in September 2019 after serving as CEO of GE’s Small Industrial Motors Division.

Exro facilitates the transition to clean energy by providing products and services to manufacturers to increase the efficiency and reliability of power systems, including electric motors, generators and batteries. Exro’s patented technology enhances energy systems by dynamically sensing and adapting variable inputs and optimally matching them to desired outputs, creating measurable performance gains and extended lifespan. The widespread applications of the technology apply to optimizing the performance of electric vehicles, UAVs, and ship drives, as well as pumps, industrial motors, and energy capture from wind and tides.

For more information, visit the company’s website at www.Exro.com

NOTE TO INVESTORS: The latest news and updates relating to EXROF are available in the company’s newsroom at http://ibn.fm/EXROF

• Shipment of medical cannabis to Israel represents a new international revenue opportunity for Supreme Cannabis
• Truverra-branded product will be sold through Israel’s largest and leading producer of medical cannabis and cannabis product
• The cannabis was grown at Supreme Cannabis’ premium, indoor, hybrid cultivation operation located in Ontario

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a company dedicated to growing the world’s best cannabis and becoming a leader in the global cannabis industry, completed a landmark shipment of medical cannabis from Canada to Israel. The shipment contained Supreme Cannabis’ premium medical cannabis product, which will be sold through Israel’s largest and leading producer of medical cannabis and cannabis product (http://ibn.fm/mocwy).

Supreme Cannabis interim president and CEO Colin Moore reported that the transaction, which was made possible through a partnership with Breath of Life International (BOL Pharma), represents a new international revenue opportunity for Supreme Cannabis and “builds Truverra’s global medical brand in one of the most sophisticated medical cannabis markets in the world.”

“With the support of BOL Pharma, we navigated both Canada and Israel’s complex regulatory landscapes to achieve compliance with regulatory authorities in both countries, including Health Canada, the Canadian Food Inspection Agency and Israel’s Ministry of Health and Ministry of Agriculture and Rural Development,” Moore continued. “We benefitted from BOL Pharma’s skilled team, international experience and solidified position as a leading medical cannabis company in Israel. As we pursue capital-light international opportunities, we will continue to look to Jeff Adams, Truverra’s CEO, and his exceptional team to build Truverra’s medical brand globally.”

Supreme Cannabis’ partner in Israel, BOL Pharma has been researching and developing cannabis-based products for more than a decade and is the only company in Israel that handles all stages of cultivation and production, ensuring compliance with the strictest standards set by the Israeli Ministry of Health and EU-GMP conditions.

Supreme Cannabis is exporting a differentiated offering to Israel. Truverra’s premium positioned medical product is indoor grown and distributed in 10-gram containers to BOL Pharma’s network of pharmacies across Israel. BOL Pharma’s CEO, Dr. Tamir Gedo, spoke to the strength of Supreme Cannabis as a partner and the quality of its product, noting, “Supreme Cannabis is a partner that shares our high standards for quality and respect for patients and consumers. On March 30, Truverra products became available across pharmacies in Israel, and we are already receiving positive feedback from patients. We look forward to continuing to work with Supreme Cannabis and to offering Truverra’s premium medical cannabis to patients in Israel.”

Supreme Cannabis acquired Truverra last year in an agreement designed to secure an international medical brand and strong team with unique pharmaceutical expertise (http://ibn.fm/yODmc). The Truverra acquisition provided a capital-light entry point into Europe’s CBD wellness market, where Truverra had successfully launched multiple CBD products through its ecommerce business, Truverra.com. This landmark shipment to Israel helps to establish Truverra as an international medical cannabis brand and provides diversified revenue opportunities for Supreme Cannabis.

The Supreme Cannabis Company is a global, diversified portfolio of distinct cannabis companies, products and brands. Since 2014, SPRWF has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies. Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including scaled cultivation, value-add processing, centralized manufacturing and product testing and research and development.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• UUUU U.S. uranium production poised to benefit from major global mine shutdowns
• Company operates three U.S. uranium facilities in Utah, Wyoming and Texas
• Energy Fuels is also leading industry efforts to encourage U.S. government to support domestically produced uranium, not cede control of U.S. nuclear sector to Russia

With many global uranium mines currently shut down because of the COVID-19 pandemic, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), the United States’ largest domestic producer of uranium, continues to operate its White Mesa Mill in Utah and is ideally poised to benefit from its reliable, stable production of uranium, which is designated by the U.S. government as vital to the nation’s security and economic prosperity. Energy Fuels also continues to maintain its two in situ recovery (ISR) facilities on standby in Wyoming and Texas.

Energy Fuels is the only U.S. company that utilizes both conventional and ISR technology to produce uranium from three different locations: the White Mesa Mill in Utah, the Nichols Ranch ISR Facility in Wyoming and the Alta Mesa ISR Facility in Texas.

The only conventional uranium and vanadium mill in the United States, UUUU’s White Mesa Mill is centered around the largest and highest-grade uranium mines and projects in the country. With licensed capacity to produce more than 8 million pounds of U3O8 per year, the facility can provide immediate scalability as uranium demand increases.

Found in the Powder River Basin, Energy Fuels’ Nichols Ranch ISR Facility has a total licensed capacity to produce 2 million pounds of U3O8 per year. The facility has significant underutilized capacity, having produced a total of 1.2 million pounds of U3O8 since commissioning in 2014. The facility is currently on standby, but the plant has significant future expansion potential as demand for uranium increases.

Located on more than 200,000 acres of private land in Texas, the Alta Mesa ISR Facility boasts a total operating capacity of 1.5 million pounds of uranium per year, and produced almost 5 million pounds of U3O8 between 2005 and 2013 before being put on standby. Although not currently operating, the plant is maintained so it can resume operation immediately to meet future expected increases in demand.

In addition to its commitment to being ready to meet the nation’s uranium needs, Energy Fuels is also leading industry efforts to encourage the U.S. government to act upon the importance of domestically produced uranium. While the United States is the largest consumer of uranium in the world, the country imports nearly 100% of this essential clean-energy metal.

The COVID-19 crisis has exposed the vulnerability of several critical U.S. supply chains including uranium imports, which are increasingly coming from Russia and China and their allies. In its efforts to change that, Energy Fuels spearheaded the 2018-2019 Uranium Section 232, which resulted in President Donald Trump creating the Nuclear Fuel Working Group (NFWG) to provide recommendations on reviving and expanding the production of nuclear fuel in the United States, including uranium. President Trump also recently announced he is seeking $1.5 billion over the next 10 years to create a U.S. strategic uranium reserve, and additional recommendations from the NFWG are expected soon.

Based in Lakewood, Colorado, Energy Fuels is the country’s largest producer of uranium and the leading conventional producer of vanadium, both of which are designated as critical minerals by the U.S. government. Energy Fuels is also evaluating opportunities to process rare earth elements, which the U.S. government has also deemed critical to U.S. national security. Energy Fuels’ uranium production portfolio stands apart, boasting more uranium production facilities, more production capacity and more in-ground resources than any other uranium producer in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years, making Energy Fuels uniquely positioned to quickly increase production to meet new demand.

For more information, visit the company’s website at www.EnergyFuels.com

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The unexpected rise of the COVID-19 pandemic has roiled markets on a global scale, but the economic outlook for China’s large electric vehicle (EV) market clearly remains promising
• Canadian mineral explorer Bolt Metals Corp. is pursuing a strategy of playing a part in China’s EV supply chain, anticipating that its Indonesian Cyclops Nickel-Cobalt project will further its plans
• Bolt is focused on the acquisition and development of production-grade EV battery metals projects in the Asia-Pacific region, anticipating that world leaders’ climate change policies will boost EVs’ fortunes
• Indonesia is working to use its metals resources to make itself a key player in the EV market, particularly in nearby China, where the stainless-steel industry is expected to be heavily reliant on Indonesian exports
• Bolt recently inked a non-binding cooperative agreement with Chinese metals producer Hunan Jinxin that advances its ties to the nation’s markets

It’s no surprise that the advent and rapid global spread of the novel coronavirus widely known as COVID-19 has disrupted production supply chains across the commercial spectrum and led to reduced market expectations for industries deemed “non-essential” during a period of pandemic-level illness that has proven deadly and debilitating for a significant portion of the world’s population.

Despite the bleak forecast for EVs and the knock-on effects on raw materials, equity analysis firm Wood Mackenzie notes that the coronavirus is an anomalous event that may disrupt the course of action taken to slow climate change, such as EV production and sales, but the overarching goal of sustaining global environments remains an irresistible driver (http://ibn.fm/vjm7d). In such a light, the long-term outlook in exploration for EV battery metals continues to look positive.

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) made news last month when the company inked a non-binding cooperative agreement with Chinese tungsten and cobalt producer Hunan Jinxin. The agreement opens the door to completing potential definitive binding agreements on mineral sourcing from Bolt’s 100 percent-controlled Cyclops Nickel-Cobalt project based in Indonesia (http://ibn.fm/T8sm1).

While extensive exploration of essential EV supply chain metals such as nickel and cobalt has been taking place at the project in Indonesia – a country known as the world’s largest nickel ore producer – Bolt Metals acknowledges that the possibility of proceeding to production at the site has yet to be established.

“The agreement does not imply that the Company has made a decision to proceed to production without first establishing mineral reserves,” a report clarification issued by Bolt Metals states. “The Company has not made the decision to proceed to production and clarifies that any such statement if made in the future would be made in compliance with Companion Policy 43-101CP, 4.2(6) – Production Decision, which requires details of the significant risks associated with such a decision.”

Even so, the agreement is expected to further Bolt’s strategy to acquire and develop production-grade battery metals opportunities throughout the Asia-Pacific region and become a participant in China’s electric vehicle supply chain. China has been a world leader in EV sales, but sales began to slow last year when the government trimmed environment-friendly subsidies. The pandemic added to the pressure, but the government is now considering reviving its incentives program to strengthen the market (http://ibn.fm/NzFly).

Indonesia has been angling to make itself a dominant player in the electric vehicle cathode supply chain thanks to its mineral resources and proximity to the Chinese market. Actions taken by the government last year were expected to make the Chinese stainless steel industry heavily reliant on Indonesia’s exports of ferro-nickel and nickel pig iron (NPI), although the unexpected effects on mineral demand brought about the pandemic outbreak in China has suspended industrial operation there on a large scale (http://ibn.fm/6AOH3).

A slight decline in NPI output in China during the first two months of the year when China was dealing with the height of its pandemic response was offset by doubled NPI supply from Indonesia, according to S&P Global Platts (http://ibn.fm/RMnoL). NPI’s substitution for high-grade nickel caused consumption of the Class-I mineral to decline, but the overall picture is that the pandemic had limited impact on nickel supply and demand in China, the energy and commodities markets analyst stated.

For more information, visit the company’s website at www.BoltMetals.com

NOTE TO INVESTORS: The latest news and updates relating to PCRCF are available in the company’s newsroom at http://ibn.fm/PCRCF

• PowerBand Solutions Cloud-based App will let consumers and dealers buy, sell, lease and trade vehicles on smart phones and computers, from anywhere
• Dealership closures due to Covid-19 may benefit PowerBand Solution’s online sales channels

PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) recently announced it has reached an agreement with RouteOne LLC (“RouteOne”) to grant up to 18,000 automotive dealerships in RouteOne’s network access to PowerBand’s unique cloud-based sales and leasing platform. It means millions of consumers will have access to PowerBand’s online platform that will “revolutionize how the world buys, sells, leases and auctions cars by making it as easy to buy a car as you now order a product on Amazon,” as PowerBand CEO Kelly Jennings stated in a news release.

PowerBand’s cloud-based platform performs a dual function – allowing retail customers to choose a vehicle from a wide variety of dealership partners and obtain a lease, with lease approvals in as little as eight seconds. The PowerBand platform also enables automobile dealerships to manage their used vehicle inventory by launching instantaneous online auctions which markets their vehicles to a vast network of the industry’s top used vehicle buyers.

American customers purchased 17.1 million new vehicles in 2019 while over 41 million used vehicles were anticipated to have changed hands last year (http://ibn.fm/nPRfJ), a staggering number largely attributable to the rising popularity of leasing. Leasing has accounted for nearly 30% of new-vehicle volumes in recent years (with an even greater 37% of Canadian vehicle buyers opting for this method of purchase), resulting in 4.1 million vehicle leases maturing in 2019 (http://ibn.fm/fberS).

Powerband Solutions’ cloud-based platform has eliminated the need for dealerships to hold physical auctions for their used and traded-in vehicle inventory, thereby reducing the high costs and lengthy timeframe associated with such sales. Rather, the ability to sell their used vehicles in an efficient and cost-effective manner will allow dealerships to save on the expenses associated with managing their inventory – and lower the cost for potential customers looking to lease a new car.

With RouteOne set to actively leverage their own salesforce to market PowerBand’s leasing and vehicle sales platform, the company is anticipating a marked increase in its transaction volumes. As CEO Kelly Jennings affirmed, “not only will PowerBand generate revenue from new and used vehicle leases, there will also be revenue generated through PowerBand’s online auction platforms as a result of consumers trading in their vehicles for new leased vehicles.”

The auto industry has been sharply affected in recent weeks as prospective buyers have shied away from vehicle purchases due to dealership closures and shelter-at-home orders. With CarMax (NYSE: KMX), the United States’ largest used-vehicle retailer, announcing recently that over half of their stores had been temporarily closed or were being operated on a limited basis due to the ongoing viral outbreak (http://ibn.fm/cR4A7), it is clear that the nation’s $350-billion used-vehicle market will rapidly have to adopt new and additional sales channels going forward. PowerBand Solutions has the transaction platform to that, and it will be widely available thanks to the RouteOne deal.

For more information, visit the company’s website at www.PowerBandSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to PWWBF are available in the company’s newsroom at http://ibn.fm/PWWBF

• Insurance technology market is rapidly growing, creating innovation and opportunity in the digital insurance sector
• InsuraGuest’s working to expand its product offering and the reach of its platform via brokers and agents
• In the hospitality sector, company’s insurance products cover a wide range of issues, from theft and damage of personal property to accidental medical expenses and accidental death and dismemberment

The insurtech market is growing rapidly, and specialized insurance provider InsuraGuest Technologies Inc. (TSX.V: ISGI) is riding the wave of technological innovation in the digital insurance sector. The company’s insurance systems target specific niches and is now moving to expand offerings to a wider audience and additional revenue streams. The company aims to move into providing software technology applicable to multiple insuring specialist sectors, of which their current support of the hospitality insurance sector is an example.

The different digital insurance needs of various markets allow InsuraGuest Technologies and other insurtech companies to provide added value by tailoring to specific needs of clients while building systems that can be adapted elsewhere.

Approximately $16.5 billion has been invested in the sector over the past 10 years. What is more, the pace of investment is on the rise (http://ibn.fm/fsRXv), with $2.2 billion raised in the first half of 2019 alone (http://ibn.fm/YWYxa). This increase is driven by outside and inside pressure for change and more innovation in the insurance market.

The growing rate of investment is essential, given that an estimated 90% of the resources insurance companies invest in technology are going into maintaining existing approaches instead of exploring real innovation. InsuraGuest, however, is adding value by offering the opposite approach – integrating insurance innovation and SaaS in a single flexible package.

InsuraGuest Technologies’ platform is set up to deliver digital insurance packages directly to partners on a business-to-business basis, and it has the technology to expand its platform to the business-to-consumer markets in the future. The company also allows agents and brokers to sign up instantly online through its fully automatized agency/broker software program. These brokers and agents then become channels to take InsuraGuest’s insurance out to their own customers, speeding up the process of distributing the insurtech innovator’s platform and products.

The company’s insurtech platform is already fully operational in the hospitality sector, where InsuraGuest offers hotels and vacation rentals easy access to the insurance coverage policies they need to protect their properties, making it easier to arrange and deliver new insurance products. Technology takes away much of the burden of arranging insurance and members can buy into all the support systems they need instead of buying a single standalone product and then struggling with making it work.

Traditional travelers’ insurance doesn’t cover a number of things that can happen inside hotels or other travel properties, putting both the traveler and the hotel or property owner at risk. People often mistakenly assume that accidents happening at such a property are covered by the property owner’s general liability or homeowner policy. InsuraGuest’s proprietary platform delivers specialized Hospitality Liability coverages that protect the hotel or vacation rental property which guests benefit from the property being protected during their stay. The Hospitality Liability Policy covers a wide range of issues, from theft and damage of personal property to accidental medical expenses, death and dismemberment.

About 59% of property managers in Europe use a specialist property management system (PMS), into which insurance typically isn’t integrated. It therefore needs to be managed separately. Recognizing this opportunity, InsuraGuest Technologies found a solution by integrating its digital insurance with 71 different PMSs around the world, gaving the software access to potentially deliver their insurance coverages to millions of rooms. This way, the process of obtaining insurance melds seamlessly with other relevant processes (http://ibn.fm/Ptvon), while allowing for significant growth opportunities for the company in larger hospitality markets.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Dedicated to the health-conscious consumer
• Expanded preclinical trial pipeline by entering into definitive agreement to acquire Tassili Life Sciences Corp
• Expanding brand into alternative medicine by entering into a definitive agreement to acquire Novoformulations

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a Canada-based company dedicated to the distribution of artisanal medicinal mushroom-infused products, is expanding its portfolio with the health-conscious consumer in mind. SHRM recently entered into a definitive agreement to acquire two separate companies: Tassili Life Sciences Corp. and Novoformulations, a specialty biotechnology company.

SHRM recently announced it has expanded its preclinical trial pipeline by entering into a definitive agreement to acquire Tassili Life Sciences Corp. (http://ibn.fm/ryRia). Under the terms of the agreement, SHRM will acquire all of the issued and outstanding shares of Tassili, equaling 16 million common shares. Tassili has filed four provisional psilocybin patents, including one relating to its work with the University of Miami around the treatment of mild traumatic brain injury (mTBI) and post traumatic stress disorder (PTSD).

Tassili is already in a partnership with a multidisciplinary team of scientists and physicians at the University of Miami that is working on developing effective treatments of mTBI with PTSD and standalone PTSD. Under a collaborative research agreement that will eventually include human clinical trials, the university will study the combination of psilocybin and cannabidiol in treating these conditions. Tassil will retain exclusive rights to inventions, data and IP discovery resulting from the studies.

“Mild traumatic brain injury, especially concussion, is a significant cause of morbidity worldwide,” Dr. Michael Hoffer, the professor leading the study at the University of Miami, stated in a release. “What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S. military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”

The goal is to shift the perception of psychedelics through the establishment of scientific underpinnings of psilocybin and cannabidiol’s medical benefits. The next step is to develop a prescription-based therapeutic medicine for mTBI with PTSD as well as a number of other disorders.

In addition to acquiring Tassili, SHRM has entered into a definitive agreement to acquire Novo Formulations Ltd. (http://ibn.fm/lVrGA). Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical industries. This acquisition will accelerate the architecture of SHRM’s patent portfolio. Under the terms of the agreement, SHRM will acquire all of the issued and outstanding shares of Novoformulations, for a total of 12.5 million common shares in the capital of the company.

Novoformulations, made up of PhD and technician-level scientists, is currently working with ketamine, anesthetics, adaptogenics, and other pharmaceutical and natural molecules. The company is actively formulating, developing and commercializing bioavailable delivery platforms.

“The existing infrastructure inherited from these recent acquisitions positions us as a leading participant throughout the entire alternative medicine life cycle,” SHRM CEO Gareth Birdsall stated in a news release. “The end result will be a turnkey solution that incorporates both standardized ingredient mixtures and pharmaceutical-grade products that can now be marketed via a variety of proprietary delivery systems. The addition of Novoformulations allows Champignon to deliver medications in a safer, more effective and more expeditious manner than our peers, from bench top in the laboratory, to preclinical and clinical trials. We are intent on the commercialization of products throughout North America, as rapidly as is safely and effectively practicable.”

Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• SHRG produces exclusive hormone-based nutritional products designed to improve physical, mental health
• Patented line of D.O.S.E. products formulated with key hormones: dopamine, oxytocin, serotonin and endorphins
• Company posts sales revenues of $169 million since December 2017 launch

Sharing Services Global Corporation (OTCQB: SHRG), a diversified direct-sales holdings company, is transforming typical sales strategies and adapting to challenging times by focusing on elevating happiness for its customers through mood-elevating nootropics products. Through its subsidiary Elepreneurs LLC, SHRG trains and supports its independent sales representatives, called Elepreneurs, to help fulfill its mission to elevate the lives of their customers through proprietary nutritional products formulated to improve physical and mental health.

Elevacity Global LLC, a second SHRG subsidiary, offers a patented line of D.O.S.E. products formulated with four hormones implicit in the brand name: dopamine, oxytocin, serotonin and endorphins. Developed by a team of experienced nutritionists, doctors, chemists, naturopaths, pharmacists and food scientists, products such as its Elevate Smart Coffee contain a proprietary blend of nootropic ingredients designed to assist with mental clarity, memory and energy.

“Within a few sips, many people say they just feel better, happy, energized and focused,” Elepreneurs Chief Experience Officer Sylvia McGrath stated in a news release (http://ibn.fm/9AfqG). “When new customers start feeling this good about an affordable product, oftentimes they feel compelled to tell other people about it. It’s an instant-impact product that oftentimes turns into an instant-impact business.”

SHRG is increasingly focused on its mission in light of current global events that have left many people isolated and depressed (http://ibn.fm/1PuCG). The company’s business model, which offers home-based entrepreneurship, online video meetings and employment flexibility, continues to serve the goals of the company despite changing economic conditions, and its mission of elevating the well-being of its employees and customers is more important – and timely – than ever.

“Are there hard days? Yes, but the good days far exceed the hard days,” Elepreneurs president Keith Halls recently observed. “It’s about more than just sharing a cup of happy coffee. It’s about helping others lead happier lives.”

Since the company’s launch in December 2017, Elevacity products have totaled $169 million in sales revenues through the Elepreneurs and Elevacity subsidiaries. Strong sales continued into 2020 with the company posting fiscal third-quarter revenues of $31.6 million for the three months ended January 31, 2020, an increase of 22% when compared to the comparable quarter of fiscal 2019 (http://ibn.fm/q1kLh).

With plans to expand into foreign markets, the company is confident in fulfilling its mission to positively affect as many lives as possible through its compelling Elepreneur opportunity and powerful Elevacity brand of health and wellness products.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Company boasts significant first-mover advantage in proprietary web-based e-commerce platform segment
• Revenue growth driven by increases in the number of registered users and acquisition of Pharmacy
• Currently adding 100+ pharmacies per month to its online purchasing platform
• Trxade seeking FDA approval for antibody rapid test that can be used for COVID-19 patients

Trxade Group Inc. (NASDAQ: MEDS) is an integrated drug delivery, procurement, and health care platform that offers health care buyers and sellers of pharmaceuticals increased profit margins. The company has developed a proprietary web-based e-commerce platform (S2P – Supplier to Pharmacy) designed to help pharmacies reduce expenses by identifying the best available supplier prices for prescription drugs nationwide.

Leveraging this approach and a robust technology based on predictive data analytics, optimum buyer/seller pricing algorithms and product availability information, Trxade is uniquely positioned to become a leading e-commerce service provider in the $500 billion U.S. pharmaceutical industry overview 2019 (http://ibn.fm/qIqYt), which comprises more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. The company targets independent pharmacies on the market, which collectively spend more than $78 billion a year (http://ibn.fm/98LSL) on branded and generic medication.

With more than 12,100 independent pharmacies registered so far, Trxade’s platform allows its members to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.

Revenue growth on the S2P platform comes from two primary sources: increases in the number of registered users and growth in the utilization rate of the trading platform among registered users according to company data. Adding approximately 100 new pharmacies per month, Trxade’s aim is to ultimately reach most, if not all, of the 24,000 independent pharmacies on the market.

The approach is part of Trxade’s efforts to be one of the driving forces behind a nationwide reduction of pharmaceutical and health care costs. Especially in the current economic climate where the health care system is under strain as a result of the ongoing pandemic, keeping medication costs is essential. To this end, the company is committed to developing its portfolio of products and services to drive value and growth for all members, employees and investors.

Trxade’s wholly owned subsidiary, Integra Pharma Solutions, has filed for an Emergency Use Authorization with the U.S. Food and Drug Administration in collaboration with its partnered manufacturer of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit (http://ibn.fm/6OuL3). Currently, the test is intended to aid in presenting a qualitative overview of antibody presence in patients who have possibly been infected by the coronavirus (COVID-19). In addition, the company aims to provide relief via another subsidiary, Bonum Health, a virtual telemedicine provider that can help patients access certified physicians and receive medical advice and prescriptions without needing to leave their homes.

This follows another innovative initiative launched via Bonum Health – the Bonum Health Hub developed in partnership with Tampa Bay-based independent retail pharmacy chain Benzer Pharmacy. Under the agreement, Bonum and Benzer set up Health Hubs in urban and rural areas to offer care to patients who can afford neither primary nor collaborative care.

As the U.S. health care market, currently valued around $4 trillion (http://ibn.fm/YqY21) is expected to continue growing in the context of an aging population, related expenses and drug costs are expected to increase at a considerable rate. This will provide significant opportunity for the Trxade model of price visibility and profit optimization, which could be successfully adopted on a wide scale by medical products and services providers.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS